A New Research Breakthrough with Jim Tananbaum

Jim Tananbaum has 25 years experience in the financial industry. As the founder, CEO & Managing Director of Foresite Capital, Mr. Tananbaum financial opportunities to build franchise healthcare businesses. He also co-founded two other companies, Theravance, Inc., and its spinoff company, Theravance BioPharma, Inc. Earning a Bachelor of Science Degree in Applied Mathematics an Computer Science from Yale University, Jim Tananbaum is also a member of Yale’s University Council and the advisory committee of the Yale School of Engineering and Applied Science.

Jim Tananbaum has extensive investment experience. He began his career as a partner in Sierra Ventures, helping to establish its investment practice. He is also a founding partner of Prospect Venture Partners II and III. His goal upon founding Foresite Capital was to combine all elements of his expertise and career. More details can be found on LinkedIn.

Foresite Capital has recently added Molly He, Ph.D. as a venture partner. According to Jim Tananbaum” Dr. He is one of the most respected scientific researchers in the area of next-generation sequencing, and we are thrilled to welcome her to the team. With her extensive expertise in genomics and drug development and her remarkable track record of leadership, she will be an invaluable resource to Foresite”. Dr. He brings more than 15 years of experience to the company.

In her previous work as senior director of scientific research at Illumina, Dr. He managed the company’s global protein reagent innovation and improvements. Prior to that role, she worked at Pacific Biosciences.

Dr. He earned her Bachelor’s Degree in Biochemistry from Nankai University and her Ph.D from the University of California at Los Angeles. She has published more than 20 papers, and also holds more than 20 patent applications and issued patents in the field of next-generation sequencing and personal medicine.

Dr. He has a goal of growing Foresite Capital’s portfolio, as well as clinical research and drug discovery.

Follow him on Twitter

See more: https://www.forbes.com/profile/jim-tananbaum/